How do you start a medical spa (med spa) business in 2027?

The outcome you should expect

A realistic single-location med spa that opens on time, hires a competent injector, and markets consistently reaches roughly $900K to $1.6M in first-full-year revenue, then stabilizes somewhere between $2.5M and $6M annually by year two or three. EBITDA margins in that mature state generally land in the 22% to 32% band. Injectable-dominant clinics — those where neuromodulators and hyaluronic acid fillers carry most of the top line — sit at the higher end, roughly 28% to 35%, because the consumable cost of a Botox unit or a filler syringe is small relative to what patients pay and the treatment consumes twenty minutes of an injector's time. Device-heavy clinics run lower, roughly 18% to 26%, because a laser platform that cost $145K to $285K has to be amortized across a treatment volume that is inherently thinner than injectables. Body-contouring-heavy clinics are lowest, roughly 16% to 24%, and that band has compressed further since GLP-1 weight-loss drugs began substituting directly for device-based fat reduction.

Breakeven typically arrives somewhere in month nine to fifteen. That number is more sensitive to injector hiring than to anything else on the pro forma. A clinic that opens with an experienced RN or NP injector who brings a patient book can hit breakeven near month seven; a clinic that opens with a newly trained injector and no book routinely takes eighteen months, and some never get there before the operator runs out of runway. This is the single largest variance driver in the entire model, and it is worth over-paying to resolve.

The cash mechanics are unusually friendly compared to almost any other medical business. Aesthetic and cosmetic work is not covered by insurance, so the practice is 100% cash-pay: no accounts receivable, no claim denials, no prior authorization, no payer mix modeling, no exposure to Medicare payment reform. Patients pay at the time of service by card, sometimes HSA where a treatment has a legitimate medical indication, and increasingly through patient financing rails like CareCredit, Cherry, and Affirm. From a RevOps standpoint this is close to a retail collections model wearing a clinical license — the revenue operations problem is demand generation and repeat-visit economics, not collections. That is genuinely different from home health, hospice, or a dermatology practice, where a large share of operational energy goes into billing infrastructure that a med spa simply does not need.

What you should not expect is a passive business. Roughly 65% to 78% of revenue at a mature clinic comes from existing patients returning — Botox every three to four months, filler every six to eighteen months, laser in series of three to six sessions. That recurrence is the whole economic engine, and it is fragile in a specific way: it attaches to the injector as much as to the practice. Plan accordingly from day one.

What drives that outcome

Five variables determine whether a med spa survives years one through three, and capital is not the top one.

Structure and supervision. In roughly thirty states, Corporate Practice of Medicine doctrine prohibits a non-physician from owning or controlling a medical-services entity. California, Texas, New York, New Jersey, Illinois, and North Carolina enforce this aggressively. A non-physician founder in those states must use the MSO/PC "friendly PC" structure: a Professional Corporation owned entirely by a licensed physician employs the clinical staff and delivers all medical services, while a Management Services Organization owned by the founder and investors provides real estate, equipment, technology, marketing, HR, and accounting under a Management Services Agreement. The MSA fee must be structured to avoid running afoul of state fee-splitting prohibitions — typically a fixed monthly fee plus a cost-plus component rather than a naked percentage of clinical revenue. A stock transfer restriction agreement lets the MSO substitute the friendly PC physician if that relationship breaks down. This is the structure every PE-backed platform uses, and it is the number-one place first-time founders get it wrong.

Scope of practice. Every state answers "who may inject" differently. Physicians may perform every aesthetic procedure everywhere. Nurse practitioners generally may inject under a collaborative practice agreement, and in full-practice-authority states may operate autonomously. Physician assistants inject under a delegation agreement per the state PA practice act. Registered nurses may typically inject under physician delegation plus a standing order — but several states materially restrict this, and North Carolina board actions have narrowed RN scope specifically in the med spa context. Most states also require a physician-conducted "good faith exam" establishing a patient-physician relationship and a treatment plan before delegated staff administer anything, and many require physician chart review within twenty-four to seventy-two hours. Estheticians work under the cosmetology board, not the medical board, and generally cannot inject or operate medical lasers.

Service mix. Typical mature mix runs 40% to 55% injectables, 15% to 25% laser and IPL, 10% to 20% body contouring and RF, 8% to 15% skincare retail, and 5% to 15% across GLP-1 weight loss, IV therapy, and hormone optimization. The mix is a margin decision disguised as a clinical one.

Acquisition economics. Customer acquisition cost runs roughly $80 to $220 per new patient through paid social, local search, review reputation, and referral. Lifetime value across a twenty-four-month patient relationship runs roughly $2,400 to $4,800. That ratio is healthy, but only if the patient actually returns — which loops back to injector retention.

Adverse-event exposure. Vascular occlusion from filler, leading to tissue necrosis or, rarely, vision loss, is the catastrophic scenario. It drives malpractice underwriting, carrier requirements, and in a real sense the entire clinical protocol stack.

Benchmarks and realistic ranges

Startup capital. A de novo single location in a permissive state runs roughly $285K to $685K. That covers 2,000 to 3,500 square feet of buildout with four to six treatment rooms, entity formation and licensure legal work in the $15K to $45K range, device leases or purchases, initial injectable stocking of $35K to $85K, a physician medical director stipend of $30K to $60K for year one, first-year insurance, and six to nine months of payroll runway. A premium flagship in a tier-1 metro — 3,500 to 6,000 square feet, six to ten treatment rooms, owned rather than leased capital equipment — runs $685K to $1.6M. Acquiring an existing operating clinic instead runs roughly $1.2M to $7M, generally priced at 0.8x to 1.6x annual revenue or 5x to 9x EBITDA, and takes two to five months to close rather than four to nine months to build.

Capital equipment. Laser and energy platforms are the second-largest line after buildout and payroll. Major platforms — Sciton, Cynosure, Lumenis, Alma, Candela, Lutronic — generally price in the $85K to $285K range per platform depending on modularity and configuration. RF microneedling systems and body-contouring devices land in similar territory. Leasing at $5K to $15K per month across three to five devices trades upfront capital for fixed monthly cost, which is usually the right call for a first location because it preserves runway during the pre-breakeven window and lets you learn which modalities your specific market actually buys before committing six figures to one.

Gross margins by line. Injectables run 65% to 75%. Laser and device treatments run 55% to 65% once equipment depreciation, consumables, and clinician time are loaded in. Body contouring runs 45% to 55% because applicator and consumable costs are higher. Skincare retail runs 70% to 85% on standard wholesale-to-retail markup. Compounded GLP-1 weight-loss programs run 30% to 45%. IV therapy and hormone optimization run 60% to 75%.

Insurance. Professional liability plus general liability at $1M/$3M minimum limits, with $2M/$5M preferred for a multi-room single location, runs roughly $25K to $185K annually depending on state, treatment mix, and claims history. Add workers' comp, property and business interruption, equipment breakdown, cyber liability (a med spa holds PHI, clinical photography, and payment data — it is a ransomware target), employment practices liability, and an umbrella layer. Total year-one insurance load for a single location realistically lands between $85K and $385K, skewing high in litigious urban markets.

Staffing. Injector base compensation generally runs $90K to $150K, with per-unit commission on neuromodulator units and per-syringe commission on filler layered on top. Top-performing RN and NP injectors in strong markets can reach $250K to $500K in total compensation. That is not a number to fight — it is the cost of the asset that generates two-thirds of your revenue. Estheticians, front-of-house coordinators, and a practice manager fill out a typical single-location team of six to twelve.

Site selection. Aesthetic discretionary spend correlates tightly with household income. A five-mile catchment with median household income below roughly $85K to $125K makes the model hard. Look for retail visibility and easy parking rather than a clinical medical-office footprint — consultation traffic behaves like retail traffic. Proximity to upscale fitness, upscale grocery, and beauty retail creates genuine cross-traffic. Then count the competition: mature metros carry fifty to two hundred competing clinics, while under-served secondary markets may carry five to twenty-five.

Risks, edge cases, and failure modes

The rent-a-doc problem. State boards in California, New Jersey, and elsewhere have pursued arrangements where a medical director collects a stipend and provides essentially no oversight. If your physician never reviews a chart, never conducts a good faith exam, and cannot be reached during an adverse event, you do not have a compliant structure — you have a legal exposure with a signature on it. Budget for real physician involvement, document it, and treat chart review as an operational SLA rather than paperwork.

Injector portability. Manufacturer loyalty programs — Allergan's Allē, Galderma's ASPIRE, and equivalents from Revance and Evolus — accrue points to the patient, and patients frequently follow the injector rather than the practice. When a top injector leaves, a meaningful slice of your repeat-visit engine can leave with them. Mitigations are structural: non-solicitation provisions where enforceable, equity or profit participation for senior injectors, deliberately building patients' relationship with the brand and front-of-house team alongside the injector, and never letting a single injector own more than a defensible share of the book.

Catastrophic adverse events. Filler injected into or compressing a vessel can cause tissue necrosis and, rarely, retinal artery occlusion with vision loss. Every treatment day requires hyaluronidase on site, a written reversal protocol every injector has rehearsed, emergency medications, an escalation path to a physician, and a transfer protocol to emergency care. Laser burns causing permanent scarring, and anaphylaxis during IV therapy, are the other two high-severity scenarios. Photographic documentation before and after every treatment, procedure-specific informed consent, and disciplined medical history and medication review are your evidentiary defense as much as your clinical one.

Compounded GLP-1 regulatory risk. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in March 2025. Once a drug is off the shortage list, compounding pharmacies lose the exemption that permitted producing what amounts to copies of an approved product, and enforcement posture tightens. If you build a weight-loss line on compounded semaglutide, you are building on ground that federal and state pharmacy regulators are actively re-grading. Treat it as an adjacency with regulatory beta, not a foundation.

Body-contouring deflation. Device-based fat reduction demand softened materially in 2023 through 2025 as GLP-1 drugs delivered results those devices were sold to deliver. The knock-on effect is real but two-sided: the same patients arrive with facial volume loss, which drives filler, biostimulator, and skin-tightening demand. Manufacturers have repositioned accordingly. If your capital plan is heavily weighted toward fat-reduction devices, stress-test it.

Advertising compliance. Before-and-after photography is the single most effective marketing asset in aesthetics and simultaneously the most regulated. FTC truth-in-advertising rules require substantiated claims and appropriate typical-result disclosure; HIPAA requires a specific patient authorization for using clinical images publicly; influencer and user-generated content require disclosure under the FTC endorsement guides. Retouched or inconsistently-lit before-and-afters are a real enforcement risk, not a stylistic choice.

Market saturation and discretionary sensitivity. Aesthetic spend tracks consumer confidence and wealth effects. A clinic underwritten on 2021 demand behavior in a saturated tier-1 metro is a fragile clinic. Secondary markets with strong household income and thin competition frequently outperform trophy locations, and the buildout costs half as much.

A practical rollout plan

Sequence matters more than speed here, because several steps gate the ones after them.

Months one and two — structure and counsel. Engage healthcare regulatory counsel with genuine med spa experience in your specific state before forming any entity. Determine your state's CPOM posture, scope-of-practice rules, good faith exam requirement, chart review window, and whether facility-level licensure applies beyond individual physician licensure. Form the MSO and PC, draft the Management Services Agreement and stock transfer restriction agreement, and identify your physician medical director. Join AmSpa for state-by-state compliance materials. Do not sign a lease before you know whether your intended ownership model is legal where you intend to operate.

Months two through four — site, capital, and licensure. Sign the lease and begin tenant improvements. Treatment rooms need adjustable tables, sinks, medical-grade lighting, lockable medication storage, sharps containers, and appropriate ventilation. Secure DEA registration in the physician's name, establish accounts with a 503A compounding pharmacy if applicable, apply for any state facility registration, and bind the insurance stack. Negotiate device leases — and negotiate hard, because aesthetic device sales carry substantial margin and quarter-end flexibility.

Months three through six — clinical staffing and protocols. Recruit your injector before you need them; this is the longest-lead item and the highest-variance one. Write standing orders and treatment protocols covering indications, contraindications, dosing, and adverse-event management for every modality you offer. Stock hyaluronidase. Establish manufacturer accounts with Allergan, Galderma, Merz, Revance, or Evolus and get the loyalty programs configured. Select and configure practice management software for scheduling, charting, photography, and point of sale.

Months five through eight — soft launch. Open with a deliberately narrow service menu — neuromodulators, one or two filler families, and one laser modality — rather than the full catalog. Every additional modality adds a protocol, a training requirement, and a liability surface. Run a soft-launch period with friends-and-family and staff treatments to shake out workflow, consent capture, photography consistency, and chart review cadence before volume arrives. Build your before-and-after library with proper authorizations from the very first patient.

Months seven onward — demand and retention. Turn on paid social and local search with disciplined CAC tracking by channel. Stand up review generation on Google and the aesthetic-specific review platforms. Launch a membership program — monthly recurring with treatment credits and member pricing — once you have enough patient volume to make the economics work; memberships convert episodic buyers into subscribers and materially smooth cash flow. Track repeat rate, average ticket, treatment mix, injector-level productivity, and CAC-to-LTV by channel as your core operating dashboard. Add modalities only when the existing menu is running near capacity.

Related questions

Can I own a med spa if I am not a doctor?

In roughly thirty Corporate Practice of Medicine states, not directly. You own a Management Services Organization that contracts with a physician-owned Professional Corporation delivering the clinical services. In more permissive states, direct ownership with a contracted medical director is workable. Verify your specific state with counsel first.

How long until a new med spa is profitable?

Breakeven typically lands between month nine and fifteen, with stabilized revenue by year two or three. The dominant variable is injector hiring: an experienced injector with an existing patient book can pull breakeven forward to roughly month seven, while an unproven injector can push it past eighteen months.

What is the highest-margin service to lead with?

Neuromodulators and hyaluronic acid fillers, at 65% to 75% gross margin, with skincare retail higher still at 70% to 85%. Injectables also generate the shortest repeat cycle — three to four months for neuromodulators — which compounds lifetime value faster than any device modality.

Should I buy an existing med spa instead of building one?

Often yes. Acquisition runs 0.8x to 1.6x revenue or 5x to 9x EBITDA and closes in two to five months versus four to nine to build. The critical diligence item is injector retention — buy the clinic without the injectors and you have bought a lease and some depreciating lasers.

Do I need a physician on site every day?

It depends entirely on your state. Some require a physician physically present for certain procedures or for a new patient's first treatment; others permit remote supervision with a good faith exam conducted via telehealth and chart review within a defined window. This is a state-specific legal question, not a general one.

FAQ

What does a physician medical director actually cost?

A stipend arrangement for oversight, chart review, protocol development, and adverse-event consultation typically runs $30K to $60K annually. If the physician also anchors injection volume as a full-time clinical employee, compensation moves into the $150K to $285K range. Structure the compensation as fixed or cost-plus rather than a percentage of clinical revenue to avoid state fee-splitting problems.

How much inventory do I need to open?

Roughly $35K to $85K in neuromodulators and $25K to $65K in fillers, covering several vials across neuromodulator brands and twenty to forty filler syringes spanning the hyaluronic acid and biostimulator categories. Stock hyaluronidase for filler reversal from day one and keep it available on every treatment day — this is a clinical requirement, not an inventory preference.

Is a med spa a good business without a clinical background?

It can be, but only if you respect what you do not know. The operators who struggle are the ones who treat clinical protocol, supervision, and adverse-event readiness as compliance overhead rather than the actual product. If you come from a business, marketing, or RevOps background, your edge is demand generation and retention economics — hire genuine clinical leadership and give it real authority over clinical decisions.

Should I lease or buy capital equipment?

Lease for a first location. Monthly device payments of $5K to $15K across three to five platforms preserve the runway you need to survive the pre-breakeven window, and leasing lets you discover which modalities your specific market actually buys before you commit $150K to $285K to a single platform. Buy once utilization is proven and the payback math clearly beats the lease.

How do I handle before-and-after photos legally?

Get a written HIPAA authorization specific to public use of the images, separate from the treatment consent. Shoot in consistent lighting from consistent angles and never retouch. Disclose typical results where a result is atypical. Require FTC-compliant disclosure from any influencer or patient posting on your behalf. Consistency protects you both legally and commercially — inconsistent photos convert worse anyway.

What single metric should I watch most closely in year one?

Repeat visit rate within ninety days of a first treatment. It is the earliest reliable signal of whether you are building a practice or just renting patients from an ad platform. Customer acquisition cost only makes sense against lifetime value, and lifetime value is entirely a function of whether people come back.

Sources

• https://www.fda.gov/drugs/human-drug-compounding/compounding-and-drug-shortages
• https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
• https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
• https://www.asds.net/
• https://www.plasticsurgery.org/news/plastic-surgery-statistics
• https://www.mbc.ca.gov/
• https://www.ncbi.nlm.nih.gov/books/NBK482154/
• https://www.sba.gov/business-guide/launch-your-business/choose-business-structure
• https://www.aslms.org/
• https://www.fda.gov/medical-devices/products-and-medical-procedures/aesthetic-cosmetic-devices

Related on PULSE

• [How do you start a dermatology practice?](/knowledge.html?q=start-dermatology-practice)
• [How do you start a wellness and IV therapy clinic?](/knowledge.html?q=start-iv-therapy-clinic)
• [How do you structure an MSO for a healthcare business?](/knowledge.html?q=mso-structure-healthcare)
• [How do you price a cash-pay medical service line?](/knowledge.html?q=cash-pay-pricing-model)
• [How do you reduce customer acquisition cost in a local service business?](/knowledge.html?q=reduce-local-cac)
• [How do you retain high-performing commissioned staff?](/knowledge.html?q=retain-commissioned-staff)